What question did this study set out to answer?

The research aims to investigate the efficacy of ELV-3111, a next-generation Type 1 RAF inhibitor, in targeting dimeric RAF-driven tumors, especially in RAS-MUT contexts.

April 5, 2026Cancer Research

Tumor-Selective RAF Targeting Using Next-Generation Type 1 Inhibitor ELV-3111

View Full Paper

Ask AI

Bookmark

Authors

MDMathieu DesaunayIcahn School of Medicine at Mount Sinai TPTara L. PetersWorcester Polytechnic Institute EMEvangelia MatenoglouAlbert Einstein College of Medicine

Discussion

Member takes

Implication

This research characterizes ELV-3111, a Type 1 RAF inhibitor that shows enhanced efficacy in RAS-mutant tumors, suggesting a renewed therapeutic approach.

Key Points

The research aims to investigate the efficacy of ELV-3111, a next-generation Type 1 RAF inhibitor, in targeting dimeric RAF-driven tumors, especially in RAS-MUT contexts.
Characterized ELV-3111 using biochemical and live-cell assays.
Conducted molecular dynamics simulations to study the mechanism of action.
Compared efficacy of ELV-3111 with other RAF inhibitors and MEK inhibitors.
Assessed therapeutic effects in various tumor models, including RAS-MUT and BRAF-MUT.
Analyzed the safety and tolerability profile of ELV-3111 in combination strategies.
ELV-3111 induces paradoxical MAPK hyperactivation selectively in normal tissues.
Achieved significant tumor regressions in both RAS-MUT and BRAF-MUT models.
Combining ELV-3111 with MEK inhibitors overcame therapeutic limitations of MAPK pathway targeting.
Enhanced tolerability compared to previous RAF inhibitors, avoiding dose-limiting toxicities.
Demonstrated a novel pharmacological interaction benefiting therapeutic strategies.

Cite This Study

Desaunay et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdd4a79560c99a0a41db https://doi.org/10.1158/1538-7445.am2026-2940

View Full Paper

Ask AI

Bookmark

Implication

This research characterizes ELV-3111, a Type 1 RAF inhibitor that shows enhanced efficacy in RAS-mutant tumors, suggesting a renewed therapeutic approach.

Tumor-Selective RAF Targeting Using Next-Generation Type 1 Inhibitor ELV-3111

Discussion

Member takes

Implication

Key Points

Cite This Study

Tumor-Selective RAF Targeting Using Next-Generation Type 1 Inhibitor ELV-3111

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider